Skip to main content
COR logo

COR · Cencora, Inc.

Track COR — free
$341.25 -7.06 (-2.03%) At close · Nov 19
Market Cap
$65.12B
Shares
190.83M
Volume · Nov 19 1.5M Avg daily vol (3M) 1.28M

Price & Indicators

 

Key stats

Close
$341.25
Open
$345.03
Day range
$337.11–347.73
52-week closing range
$252.74–374.75
Average volume, 30 days
1.4M
Short interest
3.2M · 1.7% of shares · 2.6 days
Short volume, last session
55%
Last earnings
Nov 4, 2026
Latest filing
10-Q · Aug 5
Price history
Jan 2020 to Nov 2026

Up next

Feb 3, 2027 Est · unconfirmed · in 11 wks

Latest documents

2026
Nov 4
Earnings call
Fiscal 2027 EPS guided to $19.40 to $19.75

CENCOR reported fiscal 2026 adjusted diluted EPS of $17.97, up 12%. For fiscal 2027, it guides to adjusted diluted EPS of $19.40 to $19.75, consolidated revenue growth of 3 percent to 5 percent, and operating income growth of 4% to 6%.

6 source passages
They are a CENCOR customer and have been for some time. Now, I'll provide an overview of our fiscal 2026 fourth quarter and full-year results and our fiscal 2027 financial guidance. Our purpose and dedication to our customers fueled our performance as we delivered adjusted operating income growth of 14% and adjusted diluted EPS of $17.97, up 12%. we expect adjusted diluted EPS to be in the range of $19.40 to $19.75, reflecting headline growth of 8% to 10%. We expect consolidated revenue growth to be in the range of 3 percent to 5 percent. Operating income growth is expected to be in the range of 4% to 6%. Open the document at this passage
Nov 4
Current report 8-K
New segment reporting structure begins fiscal 2027

Cencora recently completed an operating-model restructuring and will begin reporting in a new structure in the first quarter of fiscal 2027: Pharmaceutical Distribution and Services, Specialty Pharmaceutical and Provider Services, and Other.

Regulation FD disclosure
2 source passages
In order to advance its growth priorities, Cencora recently completed a restructuring of its operating model intended to strengthen execution and improve visibility. Beginning in the first quarter of fiscal 2027, the Company’s reporting structure will be comprised of Pharmaceutical Distribution and Services, Specialty Pharmaceutical and Provider Services, and Other. Open the document at this passage
Nov 4
Current report 8-K
Fiscal 2026 revenue rises 5.0%; adjusted EPS $17.97

Cencora reported fiscal 2026 revenue of $337.4 billion, up 5.0 percent, and adjusted diluted EPS of $17.97. It expects fiscal 2027 adjusted diluted EPS of $19.40 to $19.75 and increased its quarterly dividend to $0.66 per share.

Financial results, Regulation FD disclosure Read from the first part of this long document
5 source passages
Revenue increased 5.0 percent to $337.4 billion for fiscal year 2026. For fiscal year 2026, adjusted diluted EPS increased 12.3 percent to $17.97. Fiscal 2027 Adjusted Diluted EPS Expected to be in the Range of $19.40 to $19.75, reflecting growth of 8 percent to 10 percent Company increases its quarterly dividend by 10 percent On November 3, 2026, the Company declared a quarterly dividend of $0.66 per common share, a 10 percent increase in its quarterly dividend rate from $0.60 per common share. Open the document at this passage
Oct 21
Current report 8-K
Financial results, Regulation FD disclosure

Cencora agreed to acquire American Oncology Network for an enterprise value of $2.4 billion, comprising $2.3 billion at closing and contingent value rights of up to $100 million. It updated fiscal year 2026 adjusted diluted EPS expectations to at least $17.90.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$332.77B
Trailing 12 months
Net income (TTM)
$2.62B
Trailing 12 months
Revenue growth YoY
+5.1%
Year over year
Operating margin
0.9%
Trailing 12 months
P / E (TTM)
25.3
Trailing earnings · reciprocal yield 3.9%
FCF yield
6.2%
TTM · current market cap
Return on invested capital
18.6%
Trailing 12 months
Net cash
−$8.91B
Latest balance sheet
Dividend yield
0.7%
Trailing 12 months
Shares change YoY
-0.7%
Year over year · fewer shares
Price change (1Y)
-5.4%
Trailing year
Short interest
1.7%
Latest settlement · 2.6 days to cover
View all 125 metrics

AI Brief

Q4 FY26 earnings call · Nov 4, 2026
Q4 FY26

TL;DR. Fiscal 2026 delivered 5.0% revenue growth, 14.0% adjusted operating income growth and 12.3% adjusted diluted EPS growth; fiscal 2027 guidance calls for 3%–5% revenue growth, 4%–6% operating income growth and 8%–10% adjusted EPS growth. Specialty is forecast to deliver 18%–21% operating income growth in fiscal 2027, while Cencora generated $3.8 billion of free cash flow, increased its dividend 10% and plans another $1.25 billion of repurchases. Risks include an approximately 5 percentage-point operating-income headwind from Businesses and Other, distribution-segment headwinds, higher interest expense and elevated operating costs.

Bullish
Bearish
  • − Businesses and Other are expected to reduce fiscal 2027 consolidated operating income growth by approximately 5 percentage points, largely because of the assumed MWI-Covetrus merger. new
  • − Pharmaceutical Distribution and Services operating income growth is expected to be 2%–4%, including a customer volume-shift impact and an approximately $20 million foreign-exchange headwind. new
  • − Fiscal 2027 net interest expense is expected to be $490 million–$510 million, reflecting debt raised for the OneOncology transaction. new
  • − Fourth-quarter U.S. Healthcare Solutions revenue growth was partly offset by $2.8 billion of manufacturer list-price reductions and lower sales to a large mail-order customer. new
  • − Portfolio actions may create near-term financial headwinds despite concentrating resources on areas aligned with the pharmaceutical-centric strategy. new
  • − Fiscal 2026 adjusted operating expenses increased 23.7%, largely because of the OneOncology and RCA acquisitions, partly offsetting gross-profit growth. new

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Strong Sentiment Neutral Fundamentals Excellent Quant / Vol Moderate
Market backdrop VIX 28.4 · fear Equity put/call 0.72
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +8%
above
Price vs 50-day avg +4%
above
RSI (14) 51
neutral
MACD trend Negative
52-week position 73%
mid-range
Momentum
relative strength
Strong
1-month return +1%
trailing
6-month return +29%
trailing
YTD return +1%
this year
Relative strength +35%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $329 › 200d $317 — 50d above 200d
Institutional flow Accumulating
+2% holders QoQ · +145 funds added
Insider flow Distributing
Net -$4.1M over 90 days · 100% sells
Short interest Falling
1.65% of shares out · ▼ -19.7% MoM · 2.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
1,386 holders — mid 3-yr range
Squeeze score 44
elevated · 0–100
Fundamentals
Excellent
Revenue growth +9%
Y/Y
Gross margin 4%
expanding
EPS growth +6%
Y/Y
Free cash flow $3.2B
Buyback $1.9B
remaining
Balance sheet $3.3B
net debt
Quant / Vol
risk profile
Moderate
Volatility 32%
annualized · 1-yr
Max drawdown −33%
past year
ATR 2.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 1 of last 2
Latest guidance · from the 8-K filed Nov 4, 2026
Fiscal Year 2027
Adjusted diluted earnings per share Non-GAAP Initiated $19.40 – $19.75
Other adjusted operating income Non-GAAP Initiated $200M
Adjusted free cash flow Non-GAAP Initiated $3.5B
Adjusted effective tax rate Non-GAAP Initiated 20%
Fiscal Year 2027 (2% to 4% growth)
Pharmaceutical Distribution and Services adjusted operating inco Non-GAAP Initiated 2% – 4%
Fiscal Year 2027 (4% to 6% growth)
Adjusted operating income Non-GAAP Initiated 4% – 6%
Fiscal Year 2027 (18% to 21% growth)
Specialty Pharmaceutical and Provider Services adjusted operatin Non-GAAP Initiated 18% – 21%
Long-Term
Adjusted operating income long-term growth target Non-GAAP 7% – 10%
Adjusted diluted EPS long-term growth target Non-GAAP 10% – 14%
Previous outlook earlier release · from the 8-K filed Nov 5, 2025

Still-open targets the latest release did not restate under the same label.

Adjusted operating income · Long-term guidance 6% – 9%
Capital deployment · Long-term guidance 3% – 4%
Prior guidance period ended · from the 8-K filed Oct 21, 2026
Adjusted diluted earnings per share (EPS) · fiscal year 2026 at least $17.90
Guided vs delivered · last 2 settled
Net income attributable to common diluted shares 2021
guided $1.99 – $2.07
$7.39 Beat +264.0%
Net income attributable to common diluted shares 2020
guided $1.92 – $1.96
$-16.65 Miss −958.2%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+8% Bullish
Price vs 50-day avg
+4% Bullish
RSI (14)
51 Neutral
MACD trend
Negative Bearish
52-week position
73% Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $329 › 200d $317 — 50d above 200d
Institutional flow Accumulating
+2% holders QoQ · +145 funds added
Insider flow Distributing
Net -$4.1M over 90 days · 100% sells
Short interest Falling
1.65% of shares out · ▼ -19.7% MoM · 2.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
1,386 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $253 Now $341 · 73% Range high $375
vs 200-day avg +8% vs 50-day avg +4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Days inventory on hand 26.6 Three months ended June 30, 2026 filing —
Days payable outstanding 59.7 Three months ended June 30, 2026 filing —
Days sales outstanding 27.1 Three months ended June 30, 2026 filing —
U.S. Healthcare Solutions' operating income margin 1.29% the three months ended June 30, 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Distribution — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
COR
Cencora, Inc.
this stock
$65.12B +1.0% +9.3% 25.3 1.7%
MCK
Mckesson Corp
$122.63B +29.5% +3.1% 27.4 1.7%
CAH
Cardinal Health Inc
$62.95B +32.5% +14.2% — 3.3%
HSIC
Henry Schein Inc
$9.37B +12.2% +5.9% 23.2 8.5%
EBOSY
EBOS Group Limited
$2.37B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
1,386
% held
93.3%
Net QoQ
-4.9M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
1,036
View
Short & Settlement
Short Interest Falling
Shares short
3.2M
Days to cover
2.6d
Change
-776.5K sh
View
Short Volume
Short vol %
55%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
25
Value
$8.0K
As of
Oct 9, 2026
View
Off-Exchange
Off-exchange %
43.5%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$4.1M
Buyers / Sellers
0 / 2
Buyers Sellers
View
Congressional Trades Sell
Member
Jared Moskowitz
Amount
$1.0K–$15.0K
Traded
May 6, 2026
View
Financials
Financials
Revenue (FY)
$321.3B
Net income (FY)
$1.6B
EPS diluted
$7.96
View
Buybacks
Authorized
$2.0B
Remaining
$1.9B
Spent Remaining
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 4, 2026
This year
32

Cencora reported fiscal 2026 revenue of $337.4 billion, up 5.0 percent, and adjusted diluted EPS of $17.97. It expects fiscal 2027 adjusted diluted EPS of $19.40 to $19.75 and increased its quarterly dividend to $0.66 per share.

View
Proposed Sales
Value
$430.3K
Shares
1.3K
Filed
Sep 11, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 4, 2026
View
Investor Relations
Latest news
Cencora Reports Fiscal 2026 Fourt…
Published
Nov 4, 2026
View

Performance

5D 20D 120D MTD YTD
COR -2.3% +0.8% +28.9% +3.2% +1.0%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY +3.1% +7.1% +34.6% +8.4% -3.9%

Capital returns

Latest dividend
$0.66 / share · ex Nov 13, 2026
Raised 10%
Paid (TTM)
$2.46 / share · 4 payouts
Dividend yield (TTM, derived)
0.72%
Full dividend history
Buyback program · as of Jun 30, 2026
Authorized
$2.00B
Spent (derived)
$117.80M
Remaining
$1.88B
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1140859 CUSIP 03073E105 13F (30d) 1274 filings 1159 filers Visit website Investor relations